JP2013510886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510886A5 JP2013510886A5 JP2012539076A JP2012539076A JP2013510886A5 JP 2013510886 A5 JP2013510886 A5 JP 2013510886A5 JP 2012539076 A JP2012539076 A JP 2012539076A JP 2012539076 A JP2012539076 A JP 2012539076A JP 2013510886 A5 JP2013510886 A5 JP 2013510886A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- membered
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 49
- 125000003118 aryl group Chemical group 0.000 claims 41
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 39
- 229910052739 hydrogen Inorganic materials 0.000 claims 39
- 239000001257 hydrogen Substances 0.000 claims 39
- 125000004404 heteroalkyl group Chemical group 0.000 claims 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims 34
- 150000002431 hydrogen Chemical class 0.000 claims 33
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 28
- 150000002367 halogens Chemical class 0.000 claims 28
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 125000000732 arylene group Chemical group 0.000 claims 7
- 125000004474 heteroalkylene group Chemical group 0.000 claims 7
- 125000005549 heteroarylene group Chemical group 0.000 claims 7
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 7
- -1 —CF 3 Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 102000001253 Protein Kinase Human genes 0.000 claims 6
- 125000002993 cycloalkylene group Chemical group 0.000 claims 6
- 108060006633 protein kinase Proteins 0.000 claims 6
- USWQTQGAOQGPHR-UHFFFAOYSA-N 3-[4-amino-5-(4-methylphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]propan-1-ol Chemical compound C1=CC(C)=CC=C1C1=CN(CCCO)C2=NC=NC(N)=C12 USWQTQGAOQGPHR-UHFFFAOYSA-N 0.000 claims 5
- 229940043355 kinase inhibitor Drugs 0.000 claims 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 5
- 230000002441 reversible effect Effects 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 238000010276 construction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 101150086759 MAP3K1 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 0 Cc(cc1)ccc1-c1c(C=C(C(*)=O)C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(C=C(C(*)=O)C#N)[n](CCCO)c2ncnc(N)c12 0.000 description 23
- IEUOMYJAIZIKES-SFQUDFHCSA-N CC(C)(C)OC(/C(/C#N)=C/c([n](CCCO)c1ncnc(N)c11)c1-c1ccc(C)cc1)=O Chemical compound CC(C)(C)OC(/C(/C#N)=C/c([n](CCCO)c1ncnc(N)c11)c1-c1ccc(C)cc1)=O IEUOMYJAIZIKES-SFQUDFHCSA-N 0.000 description 2
- POTINGKLYOETSI-GZTJUZNOSA-N CC(C)NC(/C(/C#N)=C/c([n](CCCO)c1ncnc(N)c11)c1-c1ccc(C)cc1)=O Chemical compound CC(C)NC(/C(/C#N)=C/c([n](CCCO)c1ncnc(N)c11)c1-c1ccc(C)cc1)=O POTINGKLYOETSI-GZTJUZNOSA-N 0.000 description 2
- JOMCSJCBXRQYAV-LFIBNONCSA-N Cc(cc1)ccc1-c1c(/C=C(/C(N(C)C)=O)\C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(N(C)C)=O)\C#N)[n](CCCO)c2ncnc(N)c12 JOMCSJCBXRQYAV-LFIBNONCSA-N 0.000 description 2
- HZDYACZJZXFGHS-IZZDOVSWSA-N Cc(cc1)ccc1-c1c(/C=C(/C(N)=O)\C#N)[nH]c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(N)=O)\C#N)[nH]c2ncnc(N)c12 HZDYACZJZXFGHS-IZZDOVSWSA-N 0.000 description 2
- VGLWJTYWGAMQMT-KGENOOAVSA-N Cc(cc1)ccc1-c1c(/C=C(/C(NCc2ccccc2)=O)\C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(NCc2ccccc2)=O)\C#N)[n](CCCO)c2ncnc(N)c12 VGLWJTYWGAMQMT-KGENOOAVSA-N 0.000 description 2
- WBFCJGMKBZKZGZ-LMDBJESCSA-N CC(/C(/C1c2ccc(C)cc2)=C(/N)\N=C/N)N(CCCO)C1/C=C(/C(N(C)C)=O)\C#N Chemical compound CC(/C(/C1c2ccc(C)cc2)=C(/N)\N=C/N)N(CCCO)C1/C=C(/C(N(C)C)=O)\C#N WBFCJGMKBZKZGZ-LMDBJESCSA-N 0.000 description 1
- HZAGRSYBGQOSAL-UHFFFAOYSA-N CC(C)(CO)NC(C(CC(C(C12)c3ccc(C)cc3)N(CCCO)C1=NC=NC2N)C#N)O Chemical compound CC(C)(CO)NC(C(CC(C(C12)c3ccc(C)cc3)N(CCCO)C1=NC=NC2N)C#N)O HZAGRSYBGQOSAL-UHFFFAOYSA-N 0.000 description 1
- FEXBDPWFEBCULC-UHFFFAOYSA-N CC(C)(CO)NC(C(CC(C1c2ccc(C)cc2)N(CCCN=O)c2c1c(N)ncn2)C#N)=O Chemical compound CC(C)(CO)NC(C(CC(C1c2ccc(C)cc2)N(CCCN=O)c2c1c(N)ncn2)C#N)=O FEXBDPWFEBCULC-UHFFFAOYSA-N 0.000 description 1
- YMXATSAAJOJKBG-UHFFFAOYSA-N CC(C)NC(C(CC(C(CCCO)c1ncnc(NI)c11)=C1c1ccc(C)cc1)C#N)=O Chemical compound CC(C)NC(C(CC(C(CCCO)c1ncnc(NI)c11)=C1c1ccc(C)cc1)C#N)=O YMXATSAAJOJKBG-UHFFFAOYSA-N 0.000 description 1
- SMIILXFTIIRXRQ-CXUHLZMHSA-N CC(CC1)=CC=C1C(C12)=C(/C=C(/C(N(C3)CC3O)=O)\C#N)N(CCCO)C1=NC=NC2N Chemical compound CC(CC1)=CC=C1C(C12)=C(/C=C(/C(N(C3)CC3O)=O)\C#N)N(CCCO)C1=NC=NC2N SMIILXFTIIRXRQ-CXUHLZMHSA-N 0.000 description 1
- LTHLMMFCXLSESC-UHFFFAOYSA-O CC(c1c(CC=CCN)[n](CCCO)c(C=C(C(NC(C)(C)C)=O)C#N)c1-c1ccc(C)cc1)[NH3+] Chemical compound CC(c1c(CC=CCN)[n](CCCO)c(C=C(C(NC(C)(C)C)=O)C#N)c1-c1ccc(C)cc1)[NH3+] LTHLMMFCXLSESC-UHFFFAOYSA-O 0.000 description 1
- HUNVXONHJJSTOV-QGOAFFKASA-N Cc(cc1)ccc1-c1c(/C=C(/C(N2CCCC2)=O)\C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(N2CCCC2)=O)\C#N)[n](CCCO)c2ncnc(N)c12 HUNVXONHJJSTOV-QGOAFFKASA-N 0.000 description 1
- VDXFOORUKRSIGC-KPKJPENVSA-N Cc(cc1)ccc1-c1c(/C=C(/C(OC)=O)\C#N)[nH]c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(OC)=O)\C#N)[nH]c2ncnc(N)c12 VDXFOORUKRSIGC-KPKJPENVSA-N 0.000 description 1
- GDXHZXJALWQIPQ-XNTDXEJSSA-N Cc(cc1)ccc1-c1c(/C=C(/C(OC)=O)\C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(OC)=O)\C#N)[n](CCCO)c2ncnc(N)c12 GDXHZXJALWQIPQ-XNTDXEJSSA-N 0.000 description 1
- TXFGPVZJJSMQLS-SFQUDFHCSA-N Cc(cc1)ccc1C1=C(/C=C(/C(N2CCC2)=O)\C#N)N(CCCO)C2=NCNC(N)=C12 Chemical compound Cc(cc1)ccc1C1=C(/C=C(/C(N2CCC2)=O)\C#N)N(CCCO)C2=NCNC(N)=C12 TXFGPVZJJSMQLS-SFQUDFHCSA-N 0.000 description 1
- UKTOQAKGZCUTCX-XQNSMLJCSA-N NC(/C(/C#[N]c(cc1)ccc1-c1c(/C=C(/C(N2CCCC2)=O)\C#N)[n](CCCO)c2ncnc(N)c12)=C/c1nc2c(N)ncnc2[n]1CCCO)=O Chemical compound NC(/C(/C#[N]c(cc1)ccc1-c1c(/C=C(/C(N2CCCC2)=O)\C#N)[n](CCCO)c2ncnc(N)c12)=C/c1nc2c(N)ncnc2[n]1CCCO)=O UKTOQAKGZCUTCX-XQNSMLJCSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26169609P | 2009-11-16 | 2009-11-16 | |
| US61/261,696 | 2009-11-16 | ||
| US33027110P | 2010-04-30 | 2010-04-30 | |
| US61/330,271 | 2010-04-30 | ||
| PCT/US2010/056890 WO2011060440A2 (en) | 2009-11-16 | 2010-11-16 | Kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013510886A JP2013510886A (ja) | 2013-03-28 |
| JP2013510886A5 true JP2013510886A5 (enExample) | 2014-01-09 |
Family
ID=43992477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539076A Pending JP2013510886A (ja) | 2009-11-16 | 2010-11-16 | キナーゼ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20130035325A1 (enExample) |
| EP (1) | EP2558099A4 (enExample) |
| JP (1) | JP2013510886A (enExample) |
| CN (1) | CN102711765A (enExample) |
| AU (1) | AU2010319964A1 (enExample) |
| BR (1) | BR112012011528A2 (enExample) |
| CA (1) | CA2781056A1 (enExample) |
| MX (1) | MX2012005678A (enExample) |
| WO (1) | WO2011060440A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2710005T1 (sl) | 2011-05-17 | 2017-03-31 | Principia Biopharma Inc. | Zaviralci tirozinske kinaze |
| DK2710007T3 (da) * | 2011-05-17 | 2020-01-27 | Principia Biopharma Inc | Kinasehæmmere |
| US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| US20160045503A1 (en) | 2012-06-18 | 2016-02-18 | Principia Biopharma Inc. | Formulations containing reversible covalent compounds |
| EP2890691B1 (en) | 2012-08-31 | 2018-04-25 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
| PL2892900T3 (pl) | 2012-09-10 | 2018-02-28 | Principia Biopharma Inc. | Związki pyrazolopirymidonowe jako inhibitory kinazy |
| WO2014093230A2 (en) | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CA2939186C (en) | 2014-02-21 | 2023-03-07 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
| RU2674701C2 (ru) * | 2014-07-07 | 2018-12-12 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Аминопиридазиноновые соединения в качестве ингибиторов протеинкиназы |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| MA42242A (fr) | 2015-06-24 | 2018-05-02 | Principia Biopharma Inc | Inhibiteurs de la tyrosine kinase |
| HK1243419B (zh) | 2016-01-05 | 2019-11-22 | 江苏恒瑞医药股份有限公司 | 一种btk激酶抑制剂的结晶形式及其制备方法 |
| CN106939002B (zh) * | 2016-01-05 | 2019-09-24 | 江苏恒瑞医药股份有限公司 | 一种btk激酶抑制剂的结晶形式及其制备方法 |
| MX390619B (es) | 2016-06-29 | 2025-03-21 | Principia Biopharma Inc | Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| MX2022004427A (es) | 2019-10-14 | 2022-07-12 | Principia Biopharma Inc | Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo. |
| KR20220130184A (ko) | 2020-01-22 | 2022-09-26 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태 |
| CN111205232B (zh) * | 2020-02-26 | 2022-07-01 | 浙江天宇药业股份有限公司 | 一种替格瑞洛中间体的合成方法 |
| TW202307005A (zh) | 2021-05-28 | 2023-02-16 | 美商邊際分析公司 | 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法 |
| CN116332996B (zh) * | 2023-05-04 | 2025-04-01 | 南京颐媛生物医学研究院有限公司 | L-呋喃核糖型抗冠状病毒化合物及其制备方法和应用 |
| CN116284135B (zh) * | 2023-05-04 | 2025-03-21 | 南京颐媛生物医学研究院有限公司 | 抗冠状病毒核苷类化合物的制备方法及其应用 |
| CN116410228B (zh) * | 2023-05-04 | 2025-10-31 | 南京颐媛生物医学研究院有限公司 | 一种抗冠状病毒核苷类化合物的制备方法及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444770A (en) * | 1980-05-29 | 1984-04-24 | Bayer Aktiengesellschaft | New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use |
| DE3216416A1 (de) * | 1982-05-03 | 1983-11-03 | Bayer Ag, 5090 Leverkusen | Heteroarylthiovinyl-verbindungen, ein verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| DE3502264A1 (de) * | 1985-01-24 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Imidazoalkensaeurederivate, ein verfahren zu ihrer herstellung und ihre verwendung fuer die herstellung pharmazeutischer wirkstoffe |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DE68921643T2 (de) * | 1988-12-26 | 1995-07-06 | Zenyaku Kogyo Kk | 1-azaindolizin-derivat, zwischenprodukt dazu und antiallergisches mittel, enthaltend ein 1-azaindolizin-derivat. |
| GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JPH05301838A (ja) * | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9406137D0 (en) * | 1994-03-28 | 1994-05-18 | Erba Carlo Spa | N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation |
| GB9412719D0 (en) * | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
| US6331555B1 (en) * | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| AU2640999A (en) * | 1998-02-26 | 1999-09-15 | Zenyaku Kogyo Kabushiki Kaisha | 1-azaindolizine derivatives |
| ES2295930T3 (es) * | 2003-08-01 | 2008-04-16 | Chugai Seiyaku Kabushiki Kaisha | Compuestos de cianoamida utiles como inhibidores de malonil-coa descarboxilasa. |
| US7807719B2 (en) * | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
| EP1932833B1 (en) * | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| BRPI0709916B8 (pt) * | 2006-03-31 | 2021-05-25 | Univ Texas | drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas |
| US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
| US20100292229A1 (en) * | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| US8268809B2 (en) * | 2006-09-05 | 2012-09-18 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
| US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
-
2010
- 2010-11-16 MX MX2012005678A patent/MX2012005678A/es not_active Application Discontinuation
- 2010-11-16 US US13/510,272 patent/US20130035325A1/en not_active Abandoned
- 2010-11-16 CN CN2010800615701A patent/CN102711765A/zh active Pending
- 2010-11-16 AU AU2010319964A patent/AU2010319964A1/en not_active Abandoned
- 2010-11-16 BR BR112012011528A patent/BR112012011528A2/pt not_active IP Right Cessation
- 2010-11-16 EP EP10830919.6A patent/EP2558099A4/en not_active Withdrawn
- 2010-11-16 WO PCT/US2010/056890 patent/WO2011060440A2/en not_active Ceased
- 2010-11-16 JP JP2012539076A patent/JP2013510886A/ja active Pending
- 2010-11-16 CA CA2781056A patent/CA2781056A1/en not_active Abandoned
-
2014
- 2014-08-18 US US14/462,158 patent/US9505766B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510886A5 (enExample) | ||
| AU2018226470B2 (en) | Compounds for treatment of cancer | |
| ES2959419T3 (es) | Formulaciones secas por aspersión | |
| ES2287170T3 (es) | Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa. | |
| TWI401255B (zh) | 用以抑制有絲分裂之化合物 | |
| ES2675720T3 (es) | Inhibidores de quinasa no selectivos | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| WO2014055996A2 (en) | Rho kinase inhibitors | |
| NZ630457A (en) | Compounds useful as inhibitors of atr kinase | |
| JP2014139226A5 (enExample) | ||
| RU2011142182A (ru) | Соединения | |
| AR049769A1 (es) | Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina | |
| SI3106463T1 (en) | Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase | |
| WO2012000304A1 (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| WO2017001853A1 (en) | Antiviral compounds | |
| JP2012520861A5 (enExample) | ||
| JP2017507122A5 (enExample) | ||
| EP2769722A1 (en) | Compounds for use in inhibiting HIV capsid assembly | |
| JP2008509187A5 (enExample) | ||
| NZ592608A (en) | Benzoxazole kinase inhibitors and methods of use | |
| RU2013141274A (ru) | Содержащие фосфор соединения в качестве ингибиторов протеинкиназ | |
| WO2014079232A1 (zh) | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 | |
| JP2018502101A5 (enExample) | ||
| WO2024020221A1 (en) | Modulators of tyk2 proteolysis and associated methods of use | |
| EA200800403A1 (ru) | Производные n-(гетероарил)-1-гетероарилалкил-1н-индол-2-карбоксамидов, их получение и их применение в терапии |